Edition:
United States

Taro Pharmaceutical Industries Ltd (TARO.N)

TARO.N on New York Stock Exchange

123.39USD
29 Mar 2017
Change (% chg)

$3.27 (+2.72%)
Prev Close
$120.12
Open
$119.82
Day's High
$124.31
Day's Low
$119.82
Volume
13,688
Avg. Vol
25,875
52-wk High
$152.30
52-wk Low
$92.28

Latest Key Developments (Source: Significant Developments)

Strongbridge Biopharma announces acquisition of U.S. rights to Keveyis from Taro
Friday, 23 Dec 2016 08:01am EST 

Strongbridge Biopharma Plc : Strongbridge Biopharma Plc says taro is also eligible to receive additional future payments upon achievement of certain sales unit milestones . Strongbridge expects to commercially launch Keveyis in U.S. In April 2017 . Strongbridge Biopharma - under terms of purchase agreement, Strongbridge will provide taro with upfront and deferred payments of $8.5 million in two installments . Strongbridge Biopharma - Taro has agreed to continue to manufacture Keveyis for Strongbridge under an exclusive supply agreement at least for period of Keveyis orphan exclusivity .Strongbridge Biopharma Plc announces acquisition of U.S. Rights to Keveyis® from Taro.  Full Article

Taro Pharmaceutical Industries names Uday Baldota CEO
Tuesday, 22 Nov 2016 08:30am EST 

Taro Pharmaceutical Industries Ltd : Taro Pharmaceutical Industries Ltd- Uday Baldota as chief executive officer . Says Uday Baldota appointed CEO .Taro announces appointment of new ceo and new board member nominations.  Full Article

Taro appoints new chief financial officer
Monday, 3 Oct 2016 05:07pm EDT 

Taro Pharmaceutical Industries Ltd : Taro appoints new chief financial officer .Appointment of Mariano Balaguer as vice president, CFO and chief accounting officer, effective today.  Full Article

Taro posts qtrly earnings per share $2.59
Wednesday, 10 Aug 2016 05:12pm EDT 

Taro Pharmaceutical Industries Ltd : Taro provides results for quarter ended June 2016 . Quarterly sales $233.8 million .Quarterly earnings per share $2.59.  Full Article

Taro Pharma CEO Kal Sundaram to return to Sun Pharma headquarters by the end of 2016
Wednesday, 6 Jul 2016 05:02pm EDT 

Taro Pharmaceutical Industries Ltd : Taro ceo Kal Sundaram to return to Sun Pharma headquarters by the end of 2016 . Sundaram informed taro's board of his intention to step down as ceo by end of current calendar year .Board will conduct a formal process to appoint a ceo for taro.  Full Article

Amarin appoints Michael Kalb chief financial officer
Thursday, 30 Jun 2016 07:30am EDT 

Amarin Corporation Plc : Amarin appoints Michael Kalb chief financial officer .Kalb joins Amarin from Taro Pharmaceutical Industries Ltd.  Full Article

Taro pharmaceutical industries Q4 shr $2.68
Thursday, 26 May 2016 06:33pm EDT 

Taro Pharmaceutical Industries Ltd : Qtrly net sales of $265.1 million, increased $20.9 million, or 8.6%, on relatively flat volumes . Taro provides results for year ended march 31, 2016 . Q4 earnings per share $2.68 .Q4 sales rose 8.6 percent to $265.1 million.  Full Article

Taro Pharmaceutical Industries Ltd says FDA approves Taro's Keveyis (dichlorphenamide)
Monday, 10 Aug 2015 08:30am EDT 

Taro Pharmaceutical Industries Ltd:Says FDA has approved Keveyis (dichlorphenamide) 50 mg Tablets.For treatment of primary hyperkalemic and hypokalemic periodic paralysis, group of rare hereditary disorders that cause episodes of muscle weakness or paralysis.Keveyis is first medicine approved by FDA for treatment of primary periodic paralysis, which is estimated to affect about 5,000 people in U.S.  Full Article

More From Around the Web

BRIEF-Bellus Health to sell subsidiary Thallion Pharmaceuticals to Taro Pharmaceuticals

* Press release - Bellus Health announces the sale of subsidiary Thallion Pharmaceuticals to Taro Pharmaceuticals